Health Technology Assessment (HTA) Board
- 2017/18: Dr Hugh Gallagher, Epsom and St Helier NHS Trust, SP/17/14/33355. Aspirin To Target Arterial events in Chronic Kidney disease – the ATTACK trial. BHF awarded £750,000 over 7.5 years towards a total award of £3,937,638.
Efficacy and Mechanism Evaluation (EME) Programme
- 2016/17: Dr Peter Henriksen, University of Edinburgh, CS/17/2/32836. Multicentre prospective randomised open-label blinded end-point controlled trial of high-sensitivity cardiac troponin I-guided combination angiotensin receptor blockade and beta blocker therapy to prevent cardiac toxicity in breast cancer and lymphoma patients receiving anthracycline adjuvant therapy. BHF awarded £399,973 over 4 years towards a total grant of £965,614.
- 2010/11: Professor Derek Hausenloy, University College London, SP/10/8/28715. Joint award with MRC-EME: Effect of Remote Ischaemic preConditioning on Clinical outcomes in patients undergoing Coronary Artery bypass graft surgery (ERICCA study): a multicentre double-blind randomised controlled clinical trial. BHF awarded £340,502 over 4 years towards a total grant of £1,511,605.
- 2003/04: Professor David Taggart, University of Oxford, SP/03/001/14539. A randomised trial to compare survival following bilateral versus single internal mammary (IMA) grafting in coronary revascularisation. BHF awarded £969,535 over 10 years towards a total grant of £3.4m.